ArticleProceedings of the National Academy of Sciences of the United States of America2023
Reverse-QTY code design of active human serum albumin self-assembled amphiphilic nanoparticles for effective anti-tumor drug doxorubicin release in mice.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Exatecan-Loaded HSA Nanoparticles for Sustained Release and Enhanced Cancer Treatment.ACS omega · 2026Article
- Integrative Structural Bioinformatics and Molecular Dynamics Analyses of Synaptic Vesicle Proteins and Their Water-Soluble QTY-Variants Reveal Membrane Constraints and Evolutionary Coupling of T ⇔ V.Journal of molecular evolution · 2026Article
- Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer.Acta pharmaceutica Sinica. B · 2026Review
- Article
- Inhalable Albumin Nanoparticles Co-Delivering Dihydroartemisinin and Nintedanib Attenuate Pulmonary Fibrosis by Suppressing TGF-β1/Smad2/3 Signaling.International journal of nanomedicine · 2026Article
- Combined endovascular and surgical management of acute superior mesenteric artery embolism complicated by intestinal necrosis: a case report.Frontiers in medicine · 2026Article
- Albumin-Phthalocyanine Nanoconjugates as Platforms for Enhanced Photodynamic Cancer Therapy.International journal of molecular sciences · 2025Article
- Self-driven electrical triggering system activates tunneling nanotube highways to enhance drug delivery in bladder cancer therapy.Nature communications · 2025Article
- Biohybrid Chlorella-HSA with Self-Oxygenation and Dual-Modal activation for synergistic Photo-Sonodynamic immunotherapy.Ultrasonics sonochemistry · 2025Article
- PRO-LDM: A Conditional Latent Diffusion Model for Protein Sequence Design and Functional Optimization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Blood‑brain barrier dysfunction in epilepsy: Mechanisms, therapeutic strategies and future orientation (Review).International journal of molecular medicine · 2025Review
- Emerging nanocarriers designed for the enhanced delivery of doxorubicin.Nanomedicine (London, England) · 2025Review
- KRAS mutation-driven enhanced macropinocytosis: using albumin as a trojan horse for delivering nanomedicine.Nanomedicine (London, England) · 2025Review
- Structure Bioinformatics of Six Human Integral Transmembrane Enzymes and their AlphaFold3 Predicted Water-Soluble QTY Analogs: Insights into FACE1 and STEA4 Binding Mechanisms.Pharmaceutical research · 2025Article
- Structural bioinformatic study of human mitochondrial respiratory integral membrane megacomplex and its AlphaFold3 predicted water-soluble QTY megacomplex analog.QRB discovery · 2025Article
- Wolf in Sheep's Clothing: Taming Cancer's Resistance with Human Serum Albumin?International journal of nanomedicine · 2025Review
- Molecular Dynamic Simulations Reveal that Water-Soluble QTY-Variants of Glutamate Transporters EAA1, EAA2 and EAA3 Retain the Conformational Characteristics of Native Transporters.Pharmaceutical research · 2024Article
- Article
- Article
- GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.